Leerink Partnrs Has Negative View of Q32 Bio FY2025 Earnings

Q32 Bio Inc. (NASDAQ:QTTB) – Stock analysts at Leerink Partnrs dropped their FY2025 earnings estimates for shares of Q32 Bio in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings of ($4.37) per share for the year, down from their prior forecast of ($3.38). Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Q32 Bio’s current full-year earnings is ($12.32) per share. Leerink Partnrs also issued estimates for Q32 Bio’s FY2026 earnings at ($3.09) EPS, FY2027 earnings at ($3.59) EPS and FY2028 earnings at ($2.47) EPS.

A number of other brokerages have also recently issued reports on QTTB. BMO Capital Markets cut Q32 Bio from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $22.00 to $3.00 in a report on Tuesday. Guggenheim cut Q32 Bio from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 11th. Piper Sandler lowered shares of Q32 Bio from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $20.00 to $4.00 in a research note on Tuesday. Raymond James reissued an “outperform” rating and issued a $22.00 target price (down from $90.00) on shares of Q32 Bio in a research report on Wednesday, December 11th. Finally, Wells Fargo & Company reiterated an “equal weight” rating and issued a $16.00 target price (down previously from $95.00) on shares of Q32 Bio in a report on Wednesday, December 11th. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $24.86.

Q32 Bio Trading Down 9.4 %

Q32 Bio stock opened at $2.88 on Monday. Q32 Bio has a 1 year low of $2.60 and a 1 year high of $53.79. The firm’s 50 day moving average price is $5.92 and its two-hundred day moving average price is $28.77. The firm has a market cap of $35.08 million, a price-to-earnings ratio of -0.20 and a beta of -0.32. The company has a debt-to-equity ratio of 0.61, a quick ratio of 6.53 and a current ratio of 6.53.

Hedge Funds Weigh In On Q32 Bio

Hedge funds have recently modified their holdings of the stock. Values First Advisors Inc. bought a new stake in Q32 Bio in the third quarter valued at $33,000. Hussman Strategic Advisors Inc. acquired a new stake in shares of Q32 Bio in the 4th quarter valued at $36,000. AXQ Capital LP bought a new stake in shares of Q32 Bio in the 4th quarter worth about $36,000. Raymond James Financial Inc. acquired a new stake in shares of Q32 Bio during the 4th quarter worth about $37,000. Finally, Drive Wealth Management LLC bought a new position in Q32 Bio during the 4th quarter valued at about $38,000. 31.32% of the stock is owned by institutional investors and hedge funds.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.